A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00000853/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).
提供机构：
Vivli
创建时间：
2018-10-27
